TEL
AVIV, Israel, Nov. 30,
2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd.
(Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company
focused on the discovery and development of innovative therapeutics
for fibrotic and inflammatory diseases with high unmet need, today
announced the appointment of Mitchell L.
Jones, MD, PhD, as Vice President of Corporate Development
& Strategy. Dr. Jones brings Chemomab more than 15 years of
leadership experience in biopharmaceutical research, clinical
development, corporate strategy and entrepreneurship,
organizational development and team-building, technology transfer
and licensing and acquisitions. He will be responsible for
spearheading the corporate development function, including guiding
company strategy, tracking competitive and market developments, and
identifying, negotiating and managing partnerships and potential
acquisitions.

"Mitch has a rich combination of science and business skills and
experience that make him uniquely well qualified to lead the
corporate development function at Chemomab, and we are delighted to
have him on-board," said Dale Pfost,
PhD, Chief Executive Officer of Chemomab. "His rigorous academic
background in medicine and biomedical research is complemented by
extensive hands-on industry experience as a biotech entrepreneur,
strategist, clinical researcher, head of R&D, and dealmaker. We
look forward to benefitting from his diverse skill-set as we
advance CM-101 and work to take the company to the next stage."
Dr. Jones most recently served as Vice President Clinical
Discovery and Development at Nasdaq-listed Finch Therapeutics,
where he contributed to a successful IPO and helped oversee the
clinical development of novel therapeutics for treating
inflammatory bowel disease and cancer. Prior to Finch, Dr. Jones
served as Vice President of Translational and Clinical Development
at Nasdaq-listed Biora Therapeutics, formerly known as Progenity,
developing clinical program strategy and overseeing development of
its advanced technologies for targeted drug delivery to the GI
tract and needle-free delivery of biotherapeutics. Previously, he
served as Vice President, Innovation and Clinical Translational
Development, helping to formulate and implement a strategic roadmap
encompassing all aspects of the business while contributing to both
a $125 million venture financing and
the company's subsequent IPO.
"I am delighted to join Chemomab at this exciting time in the
company's development," said Dr. Jones. "The team's commitment to
scientific rigor and excellence, along with their drive to build on
the initial successes of CM-101, our product-in-a-pipeline
candidate for fibro-inflammatory diseases, are an excellent fit
with my background and skills. I hope to contribute in multiple
ways as we work to advance the company's current and future
programs."
Earlier, Dr. Jones helped establish and then managed the
successful trade sale of the technology platform and assets of
Interface Biosciences. Early in his career, Dr. Jones founded
Micropharma, where he served as Head of Research & Development.
He directed the development of an innovative bioinformatics
platform and multiple clinical programs, concluded major licensing
agreements with global industry partners, raised a financing round
that included non-dilutive, partnering and venture capital, and
managed the company's subsequent acquisition at a value ultimately
exceeding half a billion dollars. Dr. Jones is the author or
co-author of numerous scientific abstracts, proceedings and
publications and an inventor on almost 200 filed or granted
patents. He received his MD and PhD degrees, and a masters in
biomedical engineering and a bachelor of science degree, from
McGill University in Canada.
About Chemomab
Therapeutics
Chemomab is a clinical stage biotechnology company focusing on
the discovery and development of innovative therapeutics for
fibrotic and inflammatory diseases with high unmet need. Based on
the unique and pivotal role of the soluble protein CCL24 in
promoting fibrosis and inflammation, Chemomab developed CM-101, a
monoclonal antibody designed to bind and block CCL24 activity.
CM-101 has demonstrated the potential to treat multiple severe and
life-threatening fibrotic and inflammatory diseases. It is
currently in Phase 2 trials for primary sclerosing cholangitis and
liver fibrosis, with a Phase 2 trial in systemic sclerosis expected
to open around year-end, with first patients enrolled in early
2023. For more information on Chemomab,
visit chemomab.com.
Forward Looking
Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act. These
forward-looking statements include, among other things, statements
regarding the clinical development pathway for CM-101; the future
operations of Chemomab and its ability to successfully initiate and
complete clinical trials and achieve regulatory milestones; the
nature, strategy and focus of Chemomab; the development and
commercial potential and potential benefits of any product
candidates of Chemomab; and that the product candidates have the
potential to address high unmet needs of patients with serious
fibrosis-related diseases and conditions. Any statements contained
in this communication that are not statements of historical fact
may be deemed to be forward-looking statements. These
forward-looking statements are based upon Chemomab's current
expectations. Forward-looking statements involve risks and
uncertainties. Because such statements deal with future events and
are based on Chemomab's current expectations, they are subject to
various risks and uncertainties and actual results, performance or
achievements of Chemomab could differ materially from those
described in or implied by the statements in this presentation,
including: risks related to Chemomab's ability to effectively
implement the revised clinical strategy and its ability to achieve
the anticipated results; risks related to the projections and
associated benefits in pursuing the contemplated changes to the
clinical strategy; risks associated with the ongoing transitions of
certain of our executive officers, including Chemomab's new Chief
Executive Officer; the uncertain and time-consuming regulatory
approval process; risks related to Chemomab's ability to correctly
manage its operating expenses and its expenses; Chemomab's plans to
develop and commercialize its product candidates, focusing on
CM-101; the timing of initiation of Chemomab's planned clinical
trials; the timing of the availability of data from Chemomab's
clinical trials including any potential delays associated with
Chemomab's contemplated revised clinical strategy; the timing of
any planned investigational new drug application or new drug
application; Chemomab's plans to research, develop and
commercialize its current and future product candidates; the
clinical utility, potential benefits and market acceptance of
Chemomab's product candidates; Chemomab's commercialization,
marketing and manufacturing capabilities and strategy; Chemomab's
ability to protect its intellectual property position; and the
requirement for additional capital to continue to advance these
product candidates, which may not be available on favorable terms
or at all. Additional risks and uncertainties relating to
Chemomab's and its business can be found under the caption "Risk
Factors" and elsewhere in Chemomab's filings and reports with the
SEC. Chemomab expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in Chemomab's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based,
except to the extent required by applicable law.
Contacts:
|
|
Media:
|
Investor Relations:
|
Barbara Lindheim
|
Irina
Koffler
|
Chemomab
Therapeutics
|
LifeSci Advisors,
LLC
|
Consulting Vice
President
|
Phone:
+1-917-734-7387
|
Investor & Public
Relations,
|
ir@chemomab.com
|
Strategic
Communications
|
|
Phone:
+1-917-355-9234
|
|
barbara@chemomab.com
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chemomab-announces-appointment-of-mitchell-l-jones-md-phd-as-vice-president-of-corporate-development--strategy-301689814.html
SOURCE Chemomab Therapeutics, Ltd.